Oxbryta (Voxelotor), nouveau traitement de la dr\u00e9panocytose - SOS GLOBI<\/title>\n<meta name=\"description\" content=\"L'Agence am\u00e9ricaine du m\u00e9dicament (FDA) vient de donner l'autorisation de mise sur le march\u00e9 pour Oxbryta (Voxelotor), pour le traitement de la dr\u00e9panocytose, chez les patients \u00e2g\u00e9s de plus de 12 ans. Oxbryta devient ainsi le 4 \u00e8me traitement autoris\u00e9 aux Etats-Unis pour le traitement de la dr\u00e9panocytose, apr\u00e8s l'hydroxyur\u00e9e, Endari (L-Glutamine) et Adakveo, qui vient enrichir l'arsenal th\u00e9rapeutique.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/sosglobi.fr\/actualites\/oxbryta-voxelotor-nouveau-traitement-de-la-drepanocytose\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Oxbryta (Voxelotor), nouveau traitement de la dr\u00e9panocytose - SOS GLOBI\" \/>\n<meta property=\"og:description\" content=\"L'Agence am\u00e9ricaine du m\u00e9dicament (FDA) vient de donner l'autorisation de mise sur le march\u00e9 pour Oxbryta (Voxelotor), pour le traitement de la dr\u00e9panocytose, chez les patients \u00e2g\u00e9s de plus de 12 ans. Oxbryta devient ainsi le 4 \u00e8me traitement autoris\u00e9 aux Etats-Unis pour le traitement de la dr\u00e9panocytose, apr\u00e8s l'hydroxyur\u00e9e, Endari (L-Glutamine) et Adakveo, qui vient enrichir l'arsenal th\u00e9rapeutique.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/sosglobi.fr\/actualites\/oxbryta-voxelotor-nouveau-traitement-de-la-drepanocytose\/\" \/>\n<meta property=\"og:site_name\" content=\"SOS GLOBI\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/Federationsosglobi\" \/>\n<meta property=\"article:published_time\" content=\"2019-11-25T21:29:14+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-04-13T21:20:40+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/sosglobi.fr\/wp-content\/uploads\/2019\/11\/oxbryta-logo.png\" \/>\n\t<meta property=\"og:image:width\" content=\"319\" \/>\n\t<meta property=\"og:image:height\" content=\"158\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Sosglobi\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@FMDTsosglobi\" \/>\n<meta name=\"twitter:site\" content=\"@FMDTsosglobi\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"Sosglobi\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/sosglobi.fr\/actualites\/oxbryta-voxelotor-nouveau-traitement-de-la-drepanocytose\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/sosglobi.fr\/actualites\/oxbryta-voxelotor-nouveau-traitement-de-la-drepanocytose\/\"},\"author\":{\"name\":\"Sosglobi\",\"@id\":\"https:\/\/sosglobi.fr\/#\/schema\/person\/8b233b80feabafb288e5c0d269a0465c\"},\"headline\":\"Oxbryta (Voxelotor), nouveau traitement de la dr\u00e9panocytose\",\"datePublished\":\"2019-11-25T21:29:14+00:00\",\"dateModified\":\"2021-04-13T21:20:40+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/sosglobi.fr\/actualites\/oxbryta-voxelotor-nouveau-traitement-de-la-drepanocytose\/\"},\"wordCount\":8,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/sosglobi.fr\/#organization\"},\"articleSection\":[\"Actualit\u00e9s\"],\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/sosglobi.fr\/actualites\/oxbryta-voxelotor-nouveau-traitement-de-la-drepanocytose\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/sosglobi.fr\/actualites\/oxbryta-voxelotor-nouveau-traitement-de-la-drepanocytose\/\",\"url\":\"https:\/\/sosglobi.fr\/actualites\/oxbryta-voxelotor-nouveau-traitement-de-la-drepanocytose\/\",\"name\":\"Oxbryta (Voxelotor), nouveau traitement de la dr\u00e9panocytose - SOS GLOBI\",\"isPartOf\":{\"@id\":\"https:\/\/sosglobi.fr\/#website\"},\"datePublished\":\"2019-11-25T21:29:14+00:00\",\"dateModified\":\"2021-04-13T21:20:40+00:00\",\"description\":\"L'Agence am\u00e9ricaine du m\u00e9dicament (FDA) vient de donner l'autorisation de mise sur le march\u00e9 pour Oxbryta (Voxelotor), pour le traitement de la dr\u00e9panocytose, chez les patients \u00e2g\u00e9s de plus de 12 ans. Oxbryta devient ainsi le 4 \u00e8me traitement autoris\u00e9 aux Etats-Unis pour le traitement de la dr\u00e9panocytose, apr\u00e8s l'hydroxyur\u00e9e, Endari (L-Glutamine) et Adakveo, qui vient enrichir l'arsenal th\u00e9rapeutique.\",\"breadcrumb\":{\"@id\":\"https:\/\/sosglobi.fr\/actualites\/oxbryta-voxelotor-nouveau-traitement-de-la-drepanocytose\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/sosglobi.fr\/actualites\/oxbryta-voxelotor-nouveau-traitement-de-la-drepanocytose\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/sosglobi.fr\/actualites\/oxbryta-voxelotor-nouveau-traitement-de-la-drepanocytose\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\/\/sosglobi.fr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Actualit\u00e9s\",\"item\":\"https:\/\/sosglobi.fr\/category\/actualites\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Oxbryta (Voxelotor), nouveau traitement de la dr\u00e9panocytose\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/sosglobi.fr\/#website\",\"url\":\"https:\/\/sosglobi.fr\/\",\"name\":\"SOS GLOBI\",\"description\":\"Ensemble contre la dr\u00e9panocytose et la thalass\u00e9mie\",\"publisher\":{\"@id\":\"https:\/\/sosglobi.fr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/sosglobi.fr\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/sosglobi.fr\/#organization\",\"name\":\"F\u00e9d\u00e9ration SOS GLOBI\",\"url\":\"https:\/\/sosglobi.fr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/sosglobi.fr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/sosglobi.fr\/wp-content\/uploads\/2021\/07\/cropped-logo2lignes.png\",\"contentUrl\":\"https:\/\/sosglobi.fr\/wp-content\/uploads\/2021\/07\/cropped-logo2lignes.png\",\"width\":242,\"height\":250,\"caption\":\"F\u00e9d\u00e9ration SOS GLOBI\"},\"image\":{\"@id\":\"https:\/\/sosglobi.fr\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/Federationsosglobi\",\"https:\/\/twitter.com\/FMDTsosglobi\",\"https:\/\/www.instagram.com\/federation_sos_globi\/\",\"https:\/\/www.linkedin.com\/company\/sos-globi\/?viewAsMember=true\",\"https:\/\/www.youtube.com\/channel\/UCftpQL09xzj4eqFLFZQmUNg\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/sosglobi.fr\/#\/schema\/person\/8b233b80feabafb288e5c0d269a0465c\",\"name\":\"Sosglobi\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/sosglobi.fr\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/a0baf9e99b3c553dbb14a8ec7d51173b?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/a0baf9e99b3c553dbb14a8ec7d51173b?s=96&d=mm&r=g\",\"caption\":\"Sosglobi\"},\"url\":\"https:\/\/sosglobi.fr\/author\/conectsosglbi\/\"}]}<\/script>\n","yoast_head_json":{"title":"Oxbryta (Voxelotor), nouveau traitement de la dr\u00e9panocytose - SOS GLOBI","description":"L'Agence am\u00e9ricaine du m\u00e9dicament (FDA) vient de donner l'autorisation de mise sur le march\u00e9 pour Oxbryta (Voxelotor), pour le traitement de la dr\u00e9panocytose, chez les patients \u00e2g\u00e9s de plus de 12 ans. Oxbryta devient ainsi le 4 \u00e8me traitement autoris\u00e9 aux Etats-Unis pour le traitement de la dr\u00e9panocytose, apr\u00e8s l'hydroxyur\u00e9e, Endari (L-Glutamine) et Adakveo, qui vient enrichir l'arsenal th\u00e9rapeutique.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/sosglobi.fr\/actualites\/oxbryta-voxelotor-nouveau-traitement-de-la-drepanocytose\/","og_locale":"fr_FR","og_type":"article","og_title":"Oxbryta (Voxelotor), nouveau traitement de la dr\u00e9panocytose - SOS GLOBI","og_description":"L'Agence am\u00e9ricaine du m\u00e9dicament (FDA) vient de donner l'autorisation de mise sur le march\u00e9 pour Oxbryta (Voxelotor), pour le traitement de la dr\u00e9panocytose, chez les patients \u00e2g\u00e9s de plus de 12 ans. Oxbryta devient ainsi le 4 \u00e8me traitement autoris\u00e9 aux Etats-Unis pour le traitement de la dr\u00e9panocytose, apr\u00e8s l'hydroxyur\u00e9e, Endari (L-Glutamine) et Adakveo, qui vient enrichir l'arsenal th\u00e9rapeutique.","og_url":"https:\/\/sosglobi.fr\/actualites\/oxbryta-voxelotor-nouveau-traitement-de-la-drepanocytose\/","og_site_name":"SOS GLOBI","article_publisher":"https:\/\/www.facebook.com\/Federationsosglobi","article_published_time":"2019-11-25T21:29:14+00:00","article_modified_time":"2021-04-13T21:20:40+00:00","og_image":[{"width":319,"height":158,"url":"https:\/\/sosglobi.fr\/wp-content\/uploads\/2019\/11\/oxbryta-logo.png","type":"image\/png"}],"author":"Sosglobi","twitter_card":"summary_large_image","twitter_creator":"@FMDTsosglobi","twitter_site":"@FMDTsosglobi","twitter_misc":{"\u00c9crit par":"Sosglobi"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/sosglobi.fr\/actualites\/oxbryta-voxelotor-nouveau-traitement-de-la-drepanocytose\/#article","isPartOf":{"@id":"https:\/\/sosglobi.fr\/actualites\/oxbryta-voxelotor-nouveau-traitement-de-la-drepanocytose\/"},"author":{"name":"Sosglobi","@id":"https:\/\/sosglobi.fr\/#\/schema\/person\/8b233b80feabafb288e5c0d269a0465c"},"headline":"Oxbryta (Voxelotor), nouveau traitement de la dr\u00e9panocytose","datePublished":"2019-11-25T21:29:14+00:00","dateModified":"2021-04-13T21:20:40+00:00","mainEntityOfPage":{"@id":"https:\/\/sosglobi.fr\/actualites\/oxbryta-voxelotor-nouveau-traitement-de-la-drepanocytose\/"},"wordCount":8,"commentCount":0,"publisher":{"@id":"https:\/\/sosglobi.fr\/#organization"},"articleSection":["Actualit\u00e9s"],"inLanguage":"fr-FR","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/sosglobi.fr\/actualites\/oxbryta-voxelotor-nouveau-traitement-de-la-drepanocytose\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/sosglobi.fr\/actualites\/oxbryta-voxelotor-nouveau-traitement-de-la-drepanocytose\/","url":"https:\/\/sosglobi.fr\/actualites\/oxbryta-voxelotor-nouveau-traitement-de-la-drepanocytose\/","name":"Oxbryta (Voxelotor), nouveau traitement de la dr\u00e9panocytose - SOS GLOBI","isPartOf":{"@id":"https:\/\/sosglobi.fr\/#website"},"datePublished":"2019-11-25T21:29:14+00:00","dateModified":"2021-04-13T21:20:40+00:00","description":"L'Agence am\u00e9ricaine du m\u00e9dicament (FDA) vient de donner l'autorisation de mise sur le march\u00e9 pour Oxbryta (Voxelotor), pour le traitement de la dr\u00e9panocytose, chez les patients \u00e2g\u00e9s de plus de 12 ans. Oxbryta devient ainsi le 4 \u00e8me traitement autoris\u00e9 aux Etats-Unis pour le traitement de la dr\u00e9panocytose, apr\u00e8s l'hydroxyur\u00e9e, Endari (L-Glutamine) et Adakveo, qui vient enrichir l'arsenal th\u00e9rapeutique.","breadcrumb":{"@id":"https:\/\/sosglobi.fr\/actualites\/oxbryta-voxelotor-nouveau-traitement-de-la-drepanocytose\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/sosglobi.fr\/actualites\/oxbryta-voxelotor-nouveau-traitement-de-la-drepanocytose\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/sosglobi.fr\/actualites\/oxbryta-voxelotor-nouveau-traitement-de-la-drepanocytose\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/sosglobi.fr\/"},{"@type":"ListItem","position":2,"name":"Actualit\u00e9s","item":"https:\/\/sosglobi.fr\/category\/actualites\/"},{"@type":"ListItem","position":3,"name":"Oxbryta (Voxelotor), nouveau traitement de la dr\u00e9panocytose"}]},{"@type":"WebSite","@id":"https:\/\/sosglobi.fr\/#website","url":"https:\/\/sosglobi.fr\/","name":"SOS GLOBI","description":"Ensemble contre la dr\u00e9panocytose et la thalass\u00e9mie","publisher":{"@id":"https:\/\/sosglobi.fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/sosglobi.fr\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/sosglobi.fr\/#organization","name":"F\u00e9d\u00e9ration SOS GLOBI","url":"https:\/\/sosglobi.fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/sosglobi.fr\/#\/schema\/logo\/image\/","url":"https:\/\/sosglobi.fr\/wp-content\/uploads\/2021\/07\/cropped-logo2lignes.png","contentUrl":"https:\/\/sosglobi.fr\/wp-content\/uploads\/2021\/07\/cropped-logo2lignes.png","width":242,"height":250,"caption":"F\u00e9d\u00e9ration SOS GLOBI"},"image":{"@id":"https:\/\/sosglobi.fr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/Federationsosglobi","https:\/\/twitter.com\/FMDTsosglobi","https:\/\/www.instagram.com\/federation_sos_globi\/","https:\/\/www.linkedin.com\/company\/sos-globi\/?viewAsMember=true","https:\/\/www.youtube.com\/channel\/UCftpQL09xzj4eqFLFZQmUNg"]},{"@type":"Person","@id":"https:\/\/sosglobi.fr\/#\/schema\/person\/8b233b80feabafb288e5c0d269a0465c","name":"Sosglobi","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/sosglobi.fr\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/a0baf9e99b3c553dbb14a8ec7d51173b?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0baf9e99b3c553dbb14a8ec7d51173b?s=96&d=mm&r=g","caption":"Sosglobi"},"url":"https:\/\/sosglobi.fr\/author\/conectsosglbi\/"}]}},"_links":{"self":[{"href":"https:\/\/sosglobi.fr\/wp-json\/wp\/v2\/posts\/2848"}],"collection":[{"href":"https:\/\/sosglobi.fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/sosglobi.fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/sosglobi.fr\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/sosglobi.fr\/wp-json\/wp\/v2\/comments?post=2848"}],"version-history":[{"count":4,"href":"https:\/\/sosglobi.fr\/wp-json\/wp\/v2\/posts\/2848\/revisions"}],"predecessor-version":[{"id":3333,"href":"https:\/\/sosglobi.fr\/wp-json\/wp\/v2\/posts\/2848\/revisions\/3333"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/sosglobi.fr\/wp-json\/wp\/v2\/media\/2867"}],"wp:attachment":[{"href":"https:\/\/sosglobi.fr\/wp-json\/wp\/v2\/media?parent=2848"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/sosglobi.fr\/wp-json\/wp\/v2\/categories?post=2848"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/sosglobi.fr\/wp-json\/wp\/v2\/tags?post=2848"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}

Warning: The magic method WPML_Absolute_Url_Persisted::__wakeup() must have public visibility in /customers/6/2/a/sosglobi.fr/httpd.www/wp-content/plugins/sitepress-multilingual-cms/classes/url-handling/resolver/wpml-absolute-url-persisted.php on line 30 Warning: The magic method Gallery_Video::__wakeup() must have public visibility in /customers/6/2/a/sosglobi.fr/httpd.www/wp-content/plugins/gallery-video/video-gallery.php on line 72 Warning: Cannot modify header information - headers already sent by (output started at /customers/6/2/a/sosglobi.fr/httpd.www/wp-content/plugins/sitepress-multilingual-cms/classes/url-handling/resolver/wpml-absolute-url-persisted.php:30) in /customers/6/2/a/sosglobi.fr/httpd.www/wp-includes/rest-api/class-wp-rest-server.php on line 1762 Warning: Cannot modify header information - headers already sent by (output started at /customers/6/2/a/sosglobi.fr/httpd.www/wp-content/plugins/sitepress-multilingual-cms/classes/url-handling/resolver/wpml-absolute-url-persisted.php:30) in /customers/6/2/a/sosglobi.fr/httpd.www/wp-includes/rest-api/class-wp-rest-server.php on line 1762 Warning: Cannot modify header information - headers already sent by (output started at /customers/6/2/a/sosglobi.fr/httpd.www/wp-content/plugins/sitepress-multilingual-cms/classes/url-handling/resolver/wpml-absolute-url-persisted.php:30) in /customers/6/2/a/sosglobi.fr/httpd.www/wp-includes/rest-api/class-wp-rest-server.php on line 1762 Warning: Cannot modify header information - headers already sent by (output started at /customers/6/2/a/sosglobi.fr/httpd.www/wp-content/plugins/sitepress-multilingual-cms/classes/url-handling/resolver/wpml-absolute-url-persisted.php:30) in /customers/6/2/a/sosglobi.fr/httpd.www/wp-includes/rest-api/class-wp-rest-server.php on line 1762 Warning: Cannot modify header information - headers already sent by (output started at /customers/6/2/a/sosglobi.fr/httpd.www/wp-content/plugins/sitepress-multilingual-cms/classes/url-handling/resolver/wpml-absolute-url-persisted.php:30) in /customers/6/2/a/sosglobi.fr/httpd.www/wp-includes/rest-api/class-wp-rest-server.php on line 1762 Warning: Cannot modify header information - headers already sent by (output started at /customers/6/2/a/sosglobi.fr/httpd.www/wp-content/plugins/sitepress-multilingual-cms/classes/url-handling/resolver/wpml-absolute-url-persisted.php:30) in /customers/6/2/a/sosglobi.fr/httpd.www/wp-includes/rest-api/class-wp-rest-server.php on line 1762 Warning: Cannot modify header information - headers already sent by (output started at /customers/6/2/a/sosglobi.fr/httpd.www/wp-content/plugins/sitepress-multilingual-cms/classes/url-handling/resolver/wpml-absolute-url-persisted.php:30) in /customers/6/2/a/sosglobi.fr/httpd.www/wp-includes/rest-api/class-wp-rest-server.php on line 1762 Warning: Cannot modify header information - headers already sent by (output started at /customers/6/2/a/sosglobi.fr/httpd.www/wp-content/plugins/sitepress-multilingual-cms/classes/url-handling/resolver/wpml-absolute-url-persisted.php:30) in /customers/6/2/a/sosglobi.fr/httpd.www/wp-includes/rest-api/class-wp-rest-server.php on line 1762 {"id":2848,"date":"2019-11-25T22:29:14","date_gmt":"2019-11-25T21:29:14","guid":{"rendered":"https:\/\/sosglobi.fr\/?p=2848"},"modified":"2021-04-13T23:20:40","modified_gmt":"2021-04-13T21:20:40","slug":"oxbryta-voxelotor-nouveau-traitement-de-la-drepanocytose","status":"publish","type":"post","link":"https:\/\/sosglobi.fr\/actualites\/oxbryta-voxelotor-nouveau-traitement-de-la-drepanocytose\/","title":{"rendered":"Oxbryta (Voxelotor), nouveau traitement de la dr\u00e9panocytose"},"content":{"rendered":"","protected":false},"excerpt":{"rendered":"","protected":false},"author":2,"featured_media":2867,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[13],"tags":[],"yoast_head":"\nOxbryta (Voxelotor), nouveau traitement de la dr\u00e9panocytose - SOS GLOBI<\/title>\n<meta name=\"description\" content=\"L'Agence am\u00e9ricaine du m\u00e9dicament (FDA) vient de donner l'autorisation de mise sur le march\u00e9 pour Oxbryta (Voxelotor), pour le traitement de la dr\u00e9panocytose, chez les patients \u00e2g\u00e9s de plus de 12 ans. Oxbryta devient ainsi le 4 \u00e8me traitement autoris\u00e9 aux Etats-Unis pour le traitement de la dr\u00e9panocytose, apr\u00e8s l'hydroxyur\u00e9e, Endari (L-Glutamine) et Adakveo, qui vient enrichir l'arsenal th\u00e9rapeutique.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/sosglobi.fr\/actualites\/oxbryta-voxelotor-nouveau-traitement-de-la-drepanocytose\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Oxbryta (Voxelotor), nouveau traitement de la dr\u00e9panocytose - SOS GLOBI\" \/>\n<meta property=\"og:description\" content=\"L'Agence am\u00e9ricaine du m\u00e9dicament (FDA) vient de donner l'autorisation de mise sur le march\u00e9 pour Oxbryta (Voxelotor), pour le traitement de la dr\u00e9panocytose, chez les patients \u00e2g\u00e9s de plus de 12 ans. Oxbryta devient ainsi le 4 \u00e8me traitement autoris\u00e9 aux Etats-Unis pour le traitement de la dr\u00e9panocytose, apr\u00e8s l'hydroxyur\u00e9e, Endari (L-Glutamine) et Adakveo, qui vient enrichir l'arsenal th\u00e9rapeutique.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/sosglobi.fr\/actualites\/oxbryta-voxelotor-nouveau-traitement-de-la-drepanocytose\/\" \/>\n<meta property=\"og:site_name\" content=\"SOS GLOBI\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/Federationsosglobi\" \/>\n<meta property=\"article:published_time\" content=\"2019-11-25T21:29:14+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-04-13T21:20:40+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/sosglobi.fr\/wp-content\/uploads\/2019\/11\/oxbryta-logo.png\" \/>\n\t<meta property=\"og:image:width\" content=\"319\" \/>\n\t<meta property=\"og:image:height\" content=\"158\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Sosglobi\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@FMDTsosglobi\" \/>\n<meta name=\"twitter:site\" content=\"@FMDTsosglobi\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"Sosglobi\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/sosglobi.fr\/actualites\/oxbryta-voxelotor-nouveau-traitement-de-la-drepanocytose\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/sosglobi.fr\/actualites\/oxbryta-voxelotor-nouveau-traitement-de-la-drepanocytose\/\"},\"author\":{\"name\":\"Sosglobi\",\"@id\":\"https:\/\/sosglobi.fr\/#\/schema\/person\/8b233b80feabafb288e5c0d269a0465c\"},\"headline\":\"Oxbryta (Voxelotor), nouveau traitement de la dr\u00e9panocytose\",\"datePublished\":\"2019-11-25T21:29:14+00:00\",\"dateModified\":\"2021-04-13T21:20:40+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/sosglobi.fr\/actualites\/oxbryta-voxelotor-nouveau-traitement-de-la-drepanocytose\/\"},\"wordCount\":8,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/sosglobi.fr\/#organization\"},\"articleSection\":[\"Actualit\u00e9s\"],\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/sosglobi.fr\/actualites\/oxbryta-voxelotor-nouveau-traitement-de-la-drepanocytose\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/sosglobi.fr\/actualites\/oxbryta-voxelotor-nouveau-traitement-de-la-drepanocytose\/\",\"url\":\"https:\/\/sosglobi.fr\/actualites\/oxbryta-voxelotor-nouveau-traitement-de-la-drepanocytose\/\",\"name\":\"Oxbryta (Voxelotor), nouveau traitement de la dr\u00e9panocytose - SOS GLOBI\",\"isPartOf\":{\"@id\":\"https:\/\/sosglobi.fr\/#website\"},\"datePublished\":\"2019-11-25T21:29:14+00:00\",\"dateModified\":\"2021-04-13T21:20:40+00:00\",\"description\":\"L'Agence am\u00e9ricaine du m\u00e9dicament (FDA) vient de donner l'autorisation de mise sur le march\u00e9 pour Oxbryta (Voxelotor), pour le traitement de la dr\u00e9panocytose, chez les patients \u00e2g\u00e9s de plus de 12 ans. Oxbryta devient ainsi le 4 \u00e8me traitement autoris\u00e9 aux Etats-Unis pour le traitement de la dr\u00e9panocytose, apr\u00e8s l'hydroxyur\u00e9e, Endari (L-Glutamine) et Adakveo, qui vient enrichir l'arsenal th\u00e9rapeutique.\",\"breadcrumb\":{\"@id\":\"https:\/\/sosglobi.fr\/actualites\/oxbryta-voxelotor-nouveau-traitement-de-la-drepanocytose\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/sosglobi.fr\/actualites\/oxbryta-voxelotor-nouveau-traitement-de-la-drepanocytose\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/sosglobi.fr\/actualites\/oxbryta-voxelotor-nouveau-traitement-de-la-drepanocytose\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\/\/sosglobi.fr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Actualit\u00e9s\",\"item\":\"https:\/\/sosglobi.fr\/category\/actualites\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Oxbryta (Voxelotor), nouveau traitement de la dr\u00e9panocytose\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/sosglobi.fr\/#website\",\"url\":\"https:\/\/sosglobi.fr\/\",\"name\":\"SOS GLOBI\",\"description\":\"Ensemble contre la dr\u00e9panocytose et la thalass\u00e9mie\",\"publisher\":{\"@id\":\"https:\/\/sosglobi.fr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/sosglobi.fr\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/sosglobi.fr\/#organization\",\"name\":\"F\u00e9d\u00e9ration SOS GLOBI\",\"url\":\"https:\/\/sosglobi.fr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/sosglobi.fr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/sosglobi.fr\/wp-content\/uploads\/2021\/07\/cropped-logo2lignes.png\",\"contentUrl\":\"https:\/\/sosglobi.fr\/wp-content\/uploads\/2021\/07\/cropped-logo2lignes.png\",\"width\":242,\"height\":250,\"caption\":\"F\u00e9d\u00e9ration SOS GLOBI\"},\"image\":{\"@id\":\"https:\/\/sosglobi.fr\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/Federationsosglobi\",\"https:\/\/twitter.com\/FMDTsosglobi\",\"https:\/\/www.instagram.com\/federation_sos_globi\/\",\"https:\/\/www.linkedin.com\/company\/sos-globi\/?viewAsMember=true\",\"https:\/\/www.youtube.com\/channel\/UCftpQL09xzj4eqFLFZQmUNg\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/sosglobi.fr\/#\/schema\/person\/8b233b80feabafb288e5c0d269a0465c\",\"name\":\"Sosglobi\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/sosglobi.fr\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/a0baf9e99b3c553dbb14a8ec7d51173b?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/a0baf9e99b3c553dbb14a8ec7d51173b?s=96&d=mm&r=g\",\"caption\":\"Sosglobi\"},\"url\":\"https:\/\/sosglobi.fr\/author\/conectsosglbi\/\"}]}<\/script>\n","yoast_head_json":{"title":"Oxbryta (Voxelotor), nouveau traitement de la dr\u00e9panocytose - SOS GLOBI","description":"L'Agence am\u00e9ricaine du m\u00e9dicament (FDA) vient de donner l'autorisation de mise sur le march\u00e9 pour Oxbryta (Voxelotor), pour le traitement de la dr\u00e9panocytose, chez les patients \u00e2g\u00e9s de plus de 12 ans. Oxbryta devient ainsi le 4 \u00e8me traitement autoris\u00e9 aux Etats-Unis pour le traitement de la dr\u00e9panocytose, apr\u00e8s l'hydroxyur\u00e9e, Endari (L-Glutamine) et Adakveo, qui vient enrichir l'arsenal th\u00e9rapeutique.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/sosglobi.fr\/actualites\/oxbryta-voxelotor-nouveau-traitement-de-la-drepanocytose\/","og_locale":"fr_FR","og_type":"article","og_title":"Oxbryta (Voxelotor), nouveau traitement de la dr\u00e9panocytose - SOS GLOBI","og_description":"L'Agence am\u00e9ricaine du m\u00e9dicament (FDA) vient de donner l'autorisation de mise sur le march\u00e9 pour Oxbryta (Voxelotor), pour le traitement de la dr\u00e9panocytose, chez les patients \u00e2g\u00e9s de plus de 12 ans. Oxbryta devient ainsi le 4 \u00e8me traitement autoris\u00e9 aux Etats-Unis pour le traitement de la dr\u00e9panocytose, apr\u00e8s l'hydroxyur\u00e9e, Endari (L-Glutamine) et Adakveo, qui vient enrichir l'arsenal th\u00e9rapeutique.","og_url":"https:\/\/sosglobi.fr\/actualites\/oxbryta-voxelotor-nouveau-traitement-de-la-drepanocytose\/","og_site_name":"SOS GLOBI","article_publisher":"https:\/\/www.facebook.com\/Federationsosglobi","article_published_time":"2019-11-25T21:29:14+00:00","article_modified_time":"2021-04-13T21:20:40+00:00","og_image":[{"width":319,"height":158,"url":"https:\/\/sosglobi.fr\/wp-content\/uploads\/2019\/11\/oxbryta-logo.png","type":"image\/png"}],"author":"Sosglobi","twitter_card":"summary_large_image","twitter_creator":"@FMDTsosglobi","twitter_site":"@FMDTsosglobi","twitter_misc":{"\u00c9crit par":"Sosglobi"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/sosglobi.fr\/actualites\/oxbryta-voxelotor-nouveau-traitement-de-la-drepanocytose\/#article","isPartOf":{"@id":"https:\/\/sosglobi.fr\/actualites\/oxbryta-voxelotor-nouveau-traitement-de-la-drepanocytose\/"},"author":{"name":"Sosglobi","@id":"https:\/\/sosglobi.fr\/#\/schema\/person\/8b233b80feabafb288e5c0d269a0465c"},"headline":"Oxbryta (Voxelotor), nouveau traitement de la dr\u00e9panocytose","datePublished":"2019-11-25T21:29:14+00:00","dateModified":"2021-04-13T21:20:40+00:00","mainEntityOfPage":{"@id":"https:\/\/sosglobi.fr\/actualites\/oxbryta-voxelotor-nouveau-traitement-de-la-drepanocytose\/"},"wordCount":8,"commentCount":0,"publisher":{"@id":"https:\/\/sosglobi.fr\/#organization"},"articleSection":["Actualit\u00e9s"],"inLanguage":"fr-FR","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/sosglobi.fr\/actualites\/oxbryta-voxelotor-nouveau-traitement-de-la-drepanocytose\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/sosglobi.fr\/actualites\/oxbryta-voxelotor-nouveau-traitement-de-la-drepanocytose\/","url":"https:\/\/sosglobi.fr\/actualites\/oxbryta-voxelotor-nouveau-traitement-de-la-drepanocytose\/","name":"Oxbryta (Voxelotor), nouveau traitement de la dr\u00e9panocytose - SOS GLOBI","isPartOf":{"@id":"https:\/\/sosglobi.fr\/#website"},"datePublished":"2019-11-25T21:29:14+00:00","dateModified":"2021-04-13T21:20:40+00:00","description":"L'Agence am\u00e9ricaine du m\u00e9dicament (FDA) vient de donner l'autorisation de mise sur le march\u00e9 pour Oxbryta (Voxelotor), pour le traitement de la dr\u00e9panocytose, chez les patients \u00e2g\u00e9s de plus de 12 ans. Oxbryta devient ainsi le 4 \u00e8me traitement autoris\u00e9 aux Etats-Unis pour le traitement de la dr\u00e9panocytose, apr\u00e8s l'hydroxyur\u00e9e, Endari (L-Glutamine) et Adakveo, qui vient enrichir l'arsenal th\u00e9rapeutique.","breadcrumb":{"@id":"https:\/\/sosglobi.fr\/actualites\/oxbryta-voxelotor-nouveau-traitement-de-la-drepanocytose\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/sosglobi.fr\/actualites\/oxbryta-voxelotor-nouveau-traitement-de-la-drepanocytose\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/sosglobi.fr\/actualites\/oxbryta-voxelotor-nouveau-traitement-de-la-drepanocytose\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/sosglobi.fr\/"},{"@type":"ListItem","position":2,"name":"Actualit\u00e9s","item":"https:\/\/sosglobi.fr\/category\/actualites\/"},{"@type":"ListItem","position":3,"name":"Oxbryta (Voxelotor), nouveau traitement de la dr\u00e9panocytose"}]},{"@type":"WebSite","@id":"https:\/\/sosglobi.fr\/#website","url":"https:\/\/sosglobi.fr\/","name":"SOS GLOBI","description":"Ensemble contre la dr\u00e9panocytose et la thalass\u00e9mie","publisher":{"@id":"https:\/\/sosglobi.fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/sosglobi.fr\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/sosglobi.fr\/#organization","name":"F\u00e9d\u00e9ration SOS GLOBI","url":"https:\/\/sosglobi.fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/sosglobi.fr\/#\/schema\/logo\/image\/","url":"https:\/\/sosglobi.fr\/wp-content\/uploads\/2021\/07\/cropped-logo2lignes.png","contentUrl":"https:\/\/sosglobi.fr\/wp-content\/uploads\/2021\/07\/cropped-logo2lignes.png","width":242,"height":250,"caption":"F\u00e9d\u00e9ration SOS GLOBI"},"image":{"@id":"https:\/\/sosglobi.fr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/Federationsosglobi","https:\/\/twitter.com\/FMDTsosglobi","https:\/\/www.instagram.com\/federation_sos_globi\/","https:\/\/www.linkedin.com\/company\/sos-globi\/?viewAsMember=true","https:\/\/www.youtube.com\/channel\/UCftpQL09xzj4eqFLFZQmUNg"]},{"@type":"Person","@id":"https:\/\/sosglobi.fr\/#\/schema\/person\/8b233b80feabafb288e5c0d269a0465c","name":"Sosglobi","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/sosglobi.fr\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/a0baf9e99b3c553dbb14a8ec7d51173b?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0baf9e99b3c553dbb14a8ec7d51173b?s=96&d=mm&r=g","caption":"Sosglobi"},"url":"https:\/\/sosglobi.fr\/author\/conectsosglbi\/"}]}},"_links":{"self":[{"href":"https:\/\/sosglobi.fr\/wp-json\/wp\/v2\/posts\/2848"}],"collection":[{"href":"https:\/\/sosglobi.fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/sosglobi.fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/sosglobi.fr\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/sosglobi.fr\/wp-json\/wp\/v2\/comments?post=2848"}],"version-history":[{"count":4,"href":"https:\/\/sosglobi.fr\/wp-json\/wp\/v2\/posts\/2848\/revisions"}],"predecessor-version":[{"id":3333,"href":"https:\/\/sosglobi.fr\/wp-json\/wp\/v2\/posts\/2848\/revisions\/3333"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/sosglobi.fr\/wp-json\/wp\/v2\/media\/2867"}],"wp:attachment":[{"href":"https:\/\/sosglobi.fr\/wp-json\/wp\/v2\/media?parent=2848"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/sosglobi.fr\/wp-json\/wp\/v2\/categories?post=2848"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/sosglobi.fr\/wp-json\/wp\/v2\/tags?post=2848"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}